These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

808 related items for PubMed ID: 33309574

  • 41. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
    Cárdenas-Soto K, Dominguez XH, Cortes G, Tsai F, Saniger MDM, Guraieb-Chahin P, Torres-Ocatvo B, Gibbons C, Kelly JW, Freeman R, González-Duarte A.
    J Peripher Nerv Syst; 2024 Jun; 29(2):221-231. PubMed ID: 38706223
    [Abstract] [Full Text] [Related]

  • 42. Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.
    Tsai CH, Chao CC, Hsieh ST, Yu AL, Wu YA, Cheng MF, Lee MJ, Chou CH, Shun CT, Hsueh HW, Jyh-Ming Juang J, Tseng PH, Su MY, Lin YH.
    Orphanet J Rare Dis; 2023 Sep 13; 18(1):289. PubMed ID: 37705003
    [Abstract] [Full Text] [Related]

  • 43. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
    Capovilla TM, Lalario A, Rossi M, Porcari A, Aimo A, Limongelli G, Emdin M, Merlo M, Sinagra G.
    Heart Fail Clin; 2024 Jul 13; 20(3):333-341. PubMed ID: 38844304
    [Abstract] [Full Text] [Related]

  • 44. Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid.
    Tsai FJ, Jaeger M, Coelho T, Powers ET, Kelly JW.
    Amyloid; 2023 Sep 13; 30(3):279-289. PubMed ID: 36691999
    [Abstract] [Full Text] [Related]

  • 45. Health-related quality of life among transthyretin amyloid cardiomyopathy patients.
    Eldhagen P, Lehtonen J, Gude E, Gustafsson F, Bagger-Bahnsen A, Vakevainen M, Pilgaard T, Wedell-Wedellsborg D, Poulsen SH, Nordic PROACT study group.
    ESC Heart Fail; 2023 Jun 13; 10(3):1871-1882. PubMed ID: 36946241
    [Abstract] [Full Text] [Related]

  • 46. Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial.
    Li B, Alvir J, Stewart M.
    Cardiol Ther; 2020 Dec 13; 9(2):535-540. PubMed ID: 32524297
    [Abstract] [Full Text] [Related]

  • 47. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
    Ungericht M, Wanschitz J, Kroiss AS, Röcken C, Schuetz T, Messner M, Zaruba MM, Loescher WN, Poelzl G.
    J Nucl Cardiol; 2023 Aug 13; 30(4):1420-1426. PubMed ID: 35581484
    [Abstract] [Full Text] [Related]

  • 48. Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy.
    Falk RH, Haddad M, Walker CR, Dorbala S, Cuddy SAM.
    JACC CardioOncol; 2021 Oct 13; 3(4):580-586. PubMed ID: 34729530
    [Abstract] [Full Text] [Related]

  • 49. Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction.
    Drachman B, Damy T, Hanna M, Wang R, Angeli FS, Garcia-Pavia P.
    Eur J Heart Fail; 2024 Sep 13; 26(9):2038-2046. PubMed ID: 38932583
    [Abstract] [Full Text] [Related]

  • 50. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
    Papagianni A, Ihne S, Zeller D, Morbach C, Üçeyler N, Sommer C.
    Amyloid; 2022 Mar 13; 29(1):14-22. PubMed ID: 34632904
    [Abstract] [Full Text] [Related]

  • 51. How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary.
    Nativi-Nicolau J, Judge DP, Hoffman JE, Gundapaneni B, Keohane D, Sultan MB, Grogan M.
    Future Cardiol; 2022 Mar 17. PubMed ID: 35297655
    [Abstract] [Full Text] [Related]

  • 52. Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy.
    Streicher N, Amass L, Wang R, Stephens JM, LeMasters T, Raina R, Merrill E, Sheikh FH.
    Cardiol Ther; 2024 Jun 17; 13(2):359-368. PubMed ID: 38521883
    [Abstract] [Full Text] [Related]

  • 53. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.
    Rettl R, Mann C, Duca F, Dachs TM, Binder C, Ligios LC, Schrutka L, Dalos D, Koschutnik M, Donà C, Kammerlander A, Beitzke D, Loewe C, Charwat-Resl S, Hengstenberg C, Kastner J, Eslam RB, Bonderman D.
    Eur Heart J Cardiovasc Imaging; 2022 Jun 01; 23(6):767-780. PubMed ID: 34788394
    [Abstract] [Full Text] [Related]

  • 54. Multidisciplinary Approaches for Transthyretin Amyloidosis.
    Koike H, Okumura T, Murohara T, Katsuno M.
    Cardiol Ther; 2021 Dec 01; 10(2):289-311. PubMed ID: 34089151
    [Abstract] [Full Text] [Related]

  • 55. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
    Fujita T, Inomata T, Kaida T, Iida Y, Ikeda Y, Nabeta T, Ishii S, Maekawa E, Naruke T, Koitabashi T, Kitamura E, Sekijima Y, Ako J.
    Cardiology; 2017 Dec 01; 137(2):74-77. PubMed ID: 28152524
    [Abstract] [Full Text] [Related]

  • 56. Insights Regarding the Article "Exploring Transthyretin Amyloid Cardiomyopathy: A Comprehensive Review of the Disease and Upcoming Treatments".
    Sandeep B, Ma C, Chen J, Xiao Z.
    Curr Probl Cardiol; 2024 Jan 01; 49(1 Pt B):102100. PubMed ID: 37734690
    [Abstract] [Full Text] [Related]

  • 57. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M, Danese D, Chen C, Wang J, Wu A, Yang H, Lin H.
    Expert Opin Pharmacother; 2023 Jan 01; 24(10):1205-1214. PubMed ID: 37219406
    [Abstract] [Full Text] [Related]

  • 58. The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM): A plain language summary.
    Grogan M, Davis MK, Crespo Leiro MG, Sultan MB, Gundapaneni B, Angeli FS, Hanna M.
    Future Cardiol; 2024 Jan 01; 20(11-12):595-603. PubMed ID: 39258729
    [Abstract] [Full Text] [Related]

  • 59. Transthyretin amyloidosis: Putting myopathy on the map.
    Pinto MV, Milone M, Mauermann ML, Dyck PJB, Alhammad R, McPhail ED, Grogan M, Liewluck T.
    Muscle Nerve; 2020 Jan 01; 61(1):95-100. PubMed ID: 31587306
    [Abstract] [Full Text] [Related]

  • 60. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F, Scherret E, Knebel F, Messroghli D, Heidecker B, Wetz C, Schatka I, Barzen G, Tschöpe C, Amthauer H, Hahn K.
    Amyloid; 2022 Jun 01; 29(2):92-101. PubMed ID: 34994254
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.